| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 13152* | 2021 |
| Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM JG Viniegra, N Martínez, P Modirassari, JH Losa, CP Cobo, VJSA Lobo, ... Journal of Biological Chemistry 280 (6), 4029-4036, 2005 | 350 | 2005 |
| A role for the p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents R Sanchez-Prieto, JM Rojas, Y Taya, JS Gutkind Cancer research 60 (9), 2464-2472, 2000 | 349 | 2000 |
| Role of the p38 MAPK pathway in cisplatin-based therapy JH Losa, CP Cobo, JG Viniegra, VJSA Lobo, R Sanchez-Prieto Oncogene 22 (26), 3998-4006, 2003 | 228 | 2003 |
| HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5 A Elorza, I Soro-Arnáiz, F Meléndez-Rodríguez, V Rodríguez-Vaello, ... Molecular cell 48 (5), 681-691, 2012 | 216 | 2012 |
| Regulation of p73 by c-Abl through the p38 MAP kinase pathway R Sanchez-Prieto, VJ Sanchez-Arevalo, JM Servitja, JS Gutkind Oncogene 21 (6), 974-979, 2002 | 146 | 2002 |
| Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene. R Sanchez-Prieto, M Quintanilla, A Cano, ML Leonart, P Martin, A Anaya Oncogene 13 (5), 1083-1092, 1996 | 141 | 1996 |
| P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance MA De la Cruz-Morcillo, MLL Valero, JL Callejas-Valera, ... Oncogene 31 (9), 1073-1085, 2012 | 135 | 2012 |
| High prevalence of human papillomavirus 16 in penile carcinoma A Pascual, M Pariente, JM Godinez, R Sánchez-Prieto, M Atienzar, ... Histology and histopathology, 2007 | 78 | 2007 |
| HIF1α suppresses tumor cell proliferation through inhibition of aspartate biosynthesis F Meléndez-Rodríguez, AA Urrutia, D Lorendeau, G Rinaldi, O Roche, ... Cell reports 26 (9), 2257-2265. e4, 2019 | 71 | 2019 |
| Lack of correlation between p53 protein level and sensitivity of DNA-damaging agents in keratinocytes carrying adenovirus E1a mutants. R Sanchez-Prieto, M Lleonart Oncogene 11 (4), 675-682, 1995 | 67 | 1995 |
| p75 neurotrophin receptor and pro-BDNF promote cell survival and migration in clear cell renal cell carcinoma A Miguel, J Berger, R Sánchez-Prieto, S Saada, T Naves, A Guillaudeau, ... Oncotarget 7 (23), 34480, 2016 | 57 | 2016 |
| Hypoxia-inducible factor 2-dependent pathways driving von Hippel–Lindau-Deficient renal cancer F Meléndez-Rodríguez, O Roche, R Sanchez-Prieto, J Aragones Frontiers in oncology 8, 214, 2018 | 55 | 2018 |
| CHK1 expression in Gastric Cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy response J Bargiela-Iparraguirre, L Prado-Marchal, M Fernandez-Fuente, ... Scientific reports 6 (1), 21519, 2016 | 54 | 2016 |
| ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy CI Aceves-Luquero, A Agarwal, JL Callejas-Valera, L Arias-González, ... PloS one 4 (7), e6124, 2009 | 54 | 2009 |
| P53 pathway is a major determinant in the radiosensitizing effect of Palbociclib: Implication in cancer therapy DM Fernández-Aroca, O Roche, S Sabater, R Pascual-Serra, ... Cancer Letters 451, 23-33, 2019 | 52 | 2019 |
| Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC EM Galan-Moya, MA de la Cruz-Morcillo, ML Valero, JL Callejas-Valera, ... PloS one 6 (12), e28406, 2011 | 52 | 2011 |
| p38MAPK and chemotherapy: we always need to hear both sides of the story J García-Cano, O Roche, FJ Cimas, R Pascual-Serra, M Ortega-Muelas, ... Frontiers in cell and developmental biology 4, 69, 2016 | 50 | 2016 |
| Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance J García-Cano, G Ambroise, R Pascual-Serra, MC Carrión, ... Oncotarget 6 (17), 15551, 2015 | 50 | 2015 |
| ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma L Arias-González, I Moreno-Gimeno, AR del Campo, SO Leticia, ... Neoplasia 15 (6), 649-IN17, 2013 | 50 | 2013 |
